Search

Your search keyword '"Boguniewicz A"' showing total 820 results
Start Over Author "Boguniewicz A" Language english
820 results on '"Boguniewicz A"'

1. Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies: Ruxolitinib Cream: Phase III Patient-Reported Outcomes of Adolescents/Adults with Atopic Dermatitis

Author

Simpson, Eric L., Augustin, Matthias, Thaçi, Diamant, Misery, Laurent, Armstrong, April W., Blauvelt, Andrew, Papp, Kim A., Szepietowski, Jacek C., Boguniewicz, Mark, Kwatra, Shawn G., Kallender, Howard, Sturm, Daniel, Ren, Haobo, and Kircik, Leon

Published
2025
Full Text
View/download PDF

3. Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus

Author

Mark Boguniewicz, MD, Moise L. Levy, MD, Lawrence F. Eichenfield, MD, Christine T. Lauren, MD, MHA, Donald Y.M. Leung, MD, PhD, Lynda C. Schneider, MD, Elaine C. Siegfried, MD, Wynnis L. Tom, MD, and Amy S. Paller, MD

Subjects
pediatric eczema, topical therapy, community care, primary care providers, systemic therapy, Pediatrics, RJ1-570
Abstract

Objective: This expert-led consensus aims to provide primary care providers (PCPs) with recommendations for the care of atopic dermatitis (AD) in patients aged

Published
2024
Full Text
View/download PDF

9. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., Ramsey, Allison, Rider, Nicholas L., Schneider, Lynda, Shaker, Marcus S., Spergel, Jonathan M., Stone, Cosby A., Jr, Stukus, David R., Wang, Julie, and Greenhawt, Matthew J.

Published
2024
Full Text
View/download PDF

11. Evaluating Energy Efficiency Parameters of Municipal Wastewater Treatment Plants in Terms of Management Strategies and Carbon Footprint Reduction: Insights from Three Polish Facilities

Author

Iwona Kłosok-Bazan, Adam Rak, Joanna Boguniewicz-Zabłocka, Anna Kuczuk, and Andrea G. Capodaglio

Subjects
municipal wastewater treatment plant, energy consumption, efficiency indicators, Technology
Abstract

Water management in cities is a critical factor for sustainable growth and development. Satisfying the current needs with respect for the future is not possible without properly managed water and wastewater systems. An essential element of wastewater systems is the wastewater treatment plant (WWTP). The nexus between wastewater treatments and energy demand is a well-known problem. In times of energy crisis, effective energy management in this critical infrastructure is a key task. The purpose of this article is to analyze WWTPs’ energy consumption with regard to proposed management strategies for managers, designers and decision makers. A detailed analysis of WWTP operational parameters and a proposal of improvement actions will be useful for applicability and benchmarking studies. Estimating the carbon footprint (CF) of selected WWTPs considering the indirect emissions due to energy consumption is an important step for developing energy neutrality of WWTPs. Due to the desire to deepen research in the area of a complex phenomenon, which is the energy management system in WWTPs, the research undertaken herein is based on the case study method of three water and sewage companies operating southwestern Poland. Each urban area has different specificities, natural conditions and needs. The presented results of the analyses may be the basis for developing directions for changes in national policy, other benchmarking studies, and improving the energy management system in WWTPs.

Published
2024
Full Text
View/download PDF

12. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations

Author

Chu, Derek K., Schneider, Lynda, Asiniwasis, Rachel Netahe, Boguniewicz, Mark, De Benedetto, Anna, Ellison, Kathy, Frazier, Winfred T., Greenhawt, Matthew, Huynh, Joey, Kim, Elaine, LeBovidge, Jennifer, Lind, Mary Laura, Lio, Peter, Martin, Stephen A., O'Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Wang, Julie, Wheeler, Kathryn E., Guyatt, Gordon H., Capozza, Korey, Begolka, Wendy Smith, Chu, Alexandro W.L., Zhao, Irene X., Chen, Lina, Oykhman, Paul, Bakaa, Layla, Golden, David, Shaker, Marcus, Bernstein, Jonathan A., Horner, Caroline C., Lieberman, Jay, Stukus, David, Rank, Matthew A., Ellis, Anne, Abrams, Elissa, and Ledford, Dennis

Published
2024
Full Text
View/download PDF

15. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Author

Chu, Derek K., Chu, Alexandro W.L., Rayner, Daniel G., Guyatt, Gordon H., Yepes-Nuñez, Juan José, Gomez-Escobar, Luis, Pérez-Herrera, Lucia C., Díaz Martinez, Juan Pablo, Brignardello-Petersen, Romina, Sadeghirad, Behnam, Wong, Melanie M., Ceccacci, Renata, Zhao, Irene X., Basmaji, John, MacDonald, Margaret, Chu, Xiajing, Islam, Nazmul, Gao, Ya, Izcovich, Ariel, Asiniwasis, Rachel N., Boguniewicz, Mark, De Benedetto, Anna, Capozza, Korey, Chen, Lina, Ellison, Kathy, Frazier, Winfred T., Greenhawt, Matthew, Huynh, Joey, LeBovidge, Jennifer, Lio, Peter A., Martin, Stephen A., O’Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Smith Begolka, Wendy, Wang, Julie, Wheeler, Kathryn E., Gardner, Donna D., and Schneider, Lynda

Published
2023
Full Text
View/download PDF

16. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Author

Chu, Alexandro W.L., Wong, Melanie M., Rayner, Daniel G., Guyatt, Gordon H., Díaz Martinez, Juan Pablo, Ceccacci, Renata, Zhao, Irene X., McMullen, Eric, Srivastava, Archita, Wang, Jason, Wen, Aaron, Wang, Fang Chi, Brignardello-Petersen, Romina, Izcovich, Ariel, Oykhman, Paul, Wheeler, Kathryn E., Wang, Julie, Spergel, Jonathan M., Singh, Jasvinder A., Silverberg, Jonathan I., Ong, Peck Y., O’Brien, Monica, Martin, Stephen A., Lio, Peter A., Lind, Mary Laura, LeBovidge, Jennifer, Kim, Elaine, Huynh, Joey, Greenhawt, Matthew, Gardner, Donna D., Frazier, Winfred T., Ellison, Kathy, Chen, Lina, Capozza, Korey, De Benedetto, Anna, Boguniewicz, Mark, Smith Begolka, Wendy, Asiniwasis, Rachel N., Schneider, Lynda C., and Chu, Derek K.

Published
2023
Full Text
View/download PDF

18. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment

Author

Simpson, Eric L., Schlievert, Patrick M., Yoshida, Takeshi, Lussier, Stephanie, Boguniewicz, Mark, Hata, Tissa, Fuxench, Zelma, De Benedetto, Anna, Ong, Peck Y., Ko, Justin, Calatroni, Agustin, Rudman Spergel, Amanda K., Plaut, Marshall, Quataert, Sally A., Kilgore, Samuel H., Peterson, Liam, Gill, Ann L., David, Gloria, Mosmann, Tim, Gill, Steven R., Leung, Donald Y.M., and Beck, Lisa A.

Published
2023
Full Text
View/download PDF

25. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms

Author

Yepes-Nuñez, Juan José, Guyatt, Gordon H., Gómez-Escobar, Luis Guillermo, Pérez-Herrera, Lucia C., Chu, Alexandro W.L., Ceccaci, Renata, Acosta-Madiedo, Ana Sofía, Wen, Aaron, Moreno-López, Sergio, MacDonald, Margaret, Barrios, Mónica, Chu, Xiajing, Islam, Nazmul, Gao, Ya, Wong, Melanie M., Couban, Rachel, Garcia, Elizabeth, Chapman, Edgardo, Oykhman, Paul, Chen, Lina, Winders, Tonya, Asiniwasis, Rachel Netahe, Boguniewicz, Mark, De Benedetto, Anna, Ellison, Kathy, Frazier, Winfred T., Greenhawt, Matthew, Huynh, Joey, Kim, Elaine, LeBovidge, Jennifer, Lind, Mary Laura, Lio, Peter, Martin, Stephen A., O’Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan, Wang, Julie, Wheeler, Kathryn E., Schneider, Lynda, and Chu, Derek K.

Published
2023
Full Text
View/download PDF

28. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Author

Oykhman, Paul, Dookie, Jared, Al-Rammahy, Husam, de Benedetto, Anna, Asiniwasis, Rachel N., LeBovidge, Jennifer, Wang, Julie, Ong, Peck Y., Lio, Peter, Gutierrez, Alvin, Capozza, Korey, Martin, Stephen A., Frazier, Winfred, Wheeler, Kathryn, Boguniewicz, Mark, Spergel, Jonathan M., Greenhawt, Matthew, Silverberg, Jonathan I., Schneider, Lynda, and Chu, Derek K.

Published
2022
Full Text
View/download PDF

29. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

Author

Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, and Michael C. Cameron

Subjects
Atopic dermatitis, eczema, pruritus, quality of life, Dermatology, RL1-803
Abstract

Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated.Results Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo.Conclusion Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.ClinicalTrials.gov NCT02780167, NCT03349060, NCT03575871

Published
2022
Full Text
View/download PDF

30. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE

Author

Bakaa, Layla, Pernica, Jeffrey M., Couban, Rachel J., Tackett, Kelly Jo, Burkhart, Craig N., Leins, Liz, Smart, Joanne, Garcia-Romero, Maria Teresa, Elizalde-Jiménez, Itzel Guadalupe, Herd, Michael, Asiniwasis, Rachel Netahe, Boguniewicz, Mark, De Benedetto, Anna, Chen, Lina, Ellison, Kathy, Frazier, Winfred, Greenhawt, Matthew, Huynh, Joey, LeBovidge, Jennifer, Lind, Mary Laura, Lio, Peter, O'Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Wang, Julie, Begolka, Wendy Smith, Schneider, Lynda, and Chu, Derek K.

Published
2022
Full Text
View/download PDF

31. Atopic dermatitis: Best of guidelines and yardstick.

Author

Boguniewicz, Mark

Subjects
ALLERGY desensitization, SLEEP interruptions, ELIMINATION diets, SKIN infections, PATIENT preferences
Abstract

Background: Atopic dermatitis (AD), a common chronic inflammatory skin disorder is characterized by a complex pathology with skin-barrier abnormalities, immune dysregulation, and microbial dysbiosis. Patients' quality of life is often negatively impacted by persistent pruritus, sleep disturbance, and recurrent skin infections. In addition, patients may have comorbid atopic as well as nonatopic diseases. Objective: The objective was to help clinicians better manage AD by using new therapies and new indications, including a topical (Janus kinase [JAK]) inhibitor as well as monoclonal antibodies and oral JAK inhibitors, have been approved for AD. Methods: This review presents highlights from the American College of Allergy, Asthma and Immunology AD Yardstick Update, which incorporates Expert Commentary, and from the Joint Task Force (JTF) AD 2023 Guidelines that use Grading of Recommendations, Assessment, Development, and Evaluation methodology. Results: Practical pearls from the AD Yardstick Update Expert Commentary are presented, along with results from systematic reviews and meta-analyses that addressed specific recommendations on the role of (1) dilute bleach baths, (2) dietary avoidance and/or elimination diets, (3) allergen immunotherapy, (4) topical treatments, and (5) systemic treatments, informing the JTF 2023 AD Guidelines. These guidelines are noteworthy for addressing patient values and preferences. Conclusion: The AD Yardstick Update Expert Commentary and JTF 2023 AD Guidelines provide timely, practical, and trustworthy information to help clinicians manage patients with AD. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

35. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

Author

Boguniewicz, Mark, Beck, Lisa A., Sher, Lawrence, Guttman-Yassky, Emma, Thaçi, Diamant, Blauvelt, Andrew, Worm, Margitta, Corren, Jonathan, Soong, Weily, Lio, Peter, Rossi, Ana B., Lu, Yufang, Chao, Jingdong, Eckert, Laurent, Gadkari, Abhijit, Hultsch, Thomas, Ruddy, Marcella, Mannent, Leda P., Graham, Neil M.H., Pirozzi, Gianluca, Chen, Zhen, and Ardeleanu, Marius

Published
2021
Full Text
View/download PDF

37. Evaluating Energy Efficiency Parameters of Municipal Wastewater Treatment Plants in Terms of Management Strategies and Carbon Footprint Reduction: Insights from Three Polish Facilities.

Author

Kłosok-Bazan, Iwona, Rak, Adam, Boguniewicz-Zabłocka, Joanna, Kuczuk, Anna, and Capodaglio, Andrea G.

Subjects
SEWAGE disposal plants, SEWAGE, ENERGY management, ENERGY shortages, WASTEWATER treatment
Abstract

Water management in cities is a critical factor for sustainable growth and development. Satisfying the current needs with respect for the future is not possible without properly managed water and wastewater systems. An essential element of wastewater systems is the wastewater treatment plant (WWTP). The nexus between wastewater treatments and energy demand is a well-known problem. In times of energy crisis, effective energy management in this critical infrastructure is a key task. The purpose of this article is to analyze WWTPs' energy consumption with regard to proposed management strategies for managers, designers and decision makers. A detailed analysis of WWTP operational parameters and a proposal of improvement actions will be useful for applicability and benchmarking studies. Estimating the carbon footprint (CF) of selected WWTPs considering the indirect emissions due to energy consumption is an important step for developing energy neutrality of WWTPs. Due to the desire to deepen research in the area of a complex phenomenon, which is the energy management system in WWTPs, the research undertaken herein is based on the case study method of three water and sewage companies operating southwestern Poland. Each urban area has different specificities, natural conditions and needs. The presented results of the analyses may be the basis for developing directions for changes in national policy, other benchmarking studies, and improving the energy management system in WWTPs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Out-BREAK!: An IDWeek 2023 Escape Room to Break Out of the Educational Mold.

Author

Zhong, Diana, Dong, Sara W, Chu, Victoria T, Gabriel, Nathalie, Lusardi, Katherine, Searns, Justin B, Wattier, Rachel L, Ristagno, Elizabeth H, Bhimraj, Adarsh, Boguniewicz, Juri, and Pottinger, Paul

Subjects
ESCAPE rooms, GAMIFICATION, CLIENT satisfaction, TEAM building, CONFERENCE rooms
Abstract

Background An escape room is a cooperative game that has been adapted into medical education and major academic conferences. Methods We describe the design, development, and implementation of an educational ID-themed escape room activity entitled "Out-BREAK!" at an international conference, IDWeek 2023. An anonymous survey was conducted to collect demographic data, assess participant satisfaction with the escape room puzzles, and gauge participant interest in game-based learning. Results Thirty escape room sessions were held over 3 days and included 201 participants. Escape room survey respondents (n = 132) were younger and more likely to be trainees compared with in-person IDWeek attendants. Among 131 responses, all respondents enjoyed the experience and would recommend the escape room activity to friends. Survey respondents enjoyed the puzzle solving (93%), medical content (92%), and team building (79%) components. Only 35% of the respondents had ever previously participated in game-based learning; 95% thought the escape room was a valuable teaching method. Among the 72 survey respondents involved in medical education, almost all (90%) said they were interested in incorporating escape rooms into medical education. Conclusions The Out-BREAK! escape room at IDWeek 2023 was successfully implemented and well received. Despite only a third of participants having prior experience with game-based learning, almost all respondents perceived the escape room to be an effective teaching method. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.

Author

Eichenfield, Lawrence F., Boguniewicz, Mark, Lauren, Christine T., Leung, Donald Y.M., Levy, Moise L., Schneider, Lynda C., Siegfried, Elaine C., Tom, Wynnis L., and Paller, Amy S.

Subjects
ATOPIC dermatitis, PEDIATRIC therapy, SKIN care, CHILD patients, MEDICATION therapy management
Abstract

Atopic dermatitis (AD) is a chronic, type-2 mediated, inflammatory skin disease characterized by intense pruritus, disruption of skin barrier function, and immune dysregulation. Management strategies for AD are routinely determined based on disease severity. First-line treatment begins with basic skin care and topical anti-inflammatory medication, which is typically sufficient for the management of mild-to-moderate disease. For those patients with moderate-to-severe disease, systemic therapy is often required. This can involve off-label treatment with conventional immunosuppressant medications. However, this approach is limited by a lack of robust clinical trial data and safety concerns that necessitate close monitoring. The emergence of novel targeted biologics and small molecules to treat AD presents an opportunity to optimize AD management and patient outcomes by offering greater efficacy than traditional immunosuppressants and a favorable safety profile. As the treatment landscape shifts, clinicians can benefit from a standardized process of patient assessment and treatment, along with resources to help maintain contemporary knowledge of available therapeutic options. This US-based, expert-led consensus used a modified Delphi process to develop core recommendations for the use of systemic medications for the management of pediatric patients <18 years of age with moderate-to-severe AD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Author

Paller, Amy S., Siegfried, Elaine C., Thaçi, Diamant, Wollenberg, Andreas, Cork, Michael J., Arkwright, Peter D., Gooderham, Melinda, Beck, Lisa A., Boguniewicz, Mark, Sher, Lawrence, Weisman, Jamie, O'Malley, John T., Patel, Naimish, Hardin, Megan, Graham, Neil M.H., Ruddy, Marcella, Sun, Xian, Davis, John D., Kamal, Mohamed A., Khokhar, Faisal A., Weinreich, David M., Yancopoulos, George D., Beazley, Bethany, Bansal, Ashish, and Shumel, Brad

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results